Elevation Oncology, Inc. (ELEV)
- Previous Close
3.6450 - Open
3.6800 - Bid 3.5700 x 100
- Ask 3.6300 x 500
- Day's Range
3.5799 - 3.8300 - 52 Week Range
0.3630 - 5.8900 - Volume
872,449 - Avg. Volume
1,171,028 - Market Cap (intraday)
176.117M - Beta (5Y Monthly) 1.36
- PE Ratio (TTM)
-- - EPS (TTM)
-1.3400 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.75
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.
elevationoncology.comRecent News: ELEV
Performance Overview: ELEV
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ELEV
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ELEV
Valuation Measures
Market Cap
176.12M
Enterprise Value
123.15M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.21
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-2.97
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-27.52%
Return on Equity (ttm)
-88.03%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-45.7M
Diluted EPS (ttm)
-1.3400
Balance Sheet and Cash Flow
Total Cash (mrq)
83.11M
Total Debt/Equity (mrq)
54.98%
Levered Free Cash Flow (ttm)
-38.17M